Identification of recurrent SMO and BRAF mutations in ameloblastomas

Robert T. Sweeney, Andrew C. McClary, Benjamin R. Myers, Jewison Biscocho, Lila Neahring, Kevin A. Kwei, Kunbin Qu, Xue Gong, Tony Ng, Carol D. Jones, Sushama Varma, Justin I. Odegaard, Toshihiro Sugiyama, Souichi Koyota, Brian P. Rubin, Megan Troxell, Robert J. Pelham, James L. Zehnder, Philip A. Beachy, Jonathan R. Pollack & 1 others Robert B. West

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Here we report the discovery of oncogenic mutations in the Hedgehog and mitogen-activated protein kinase (MAPK) pathways in over 80% of ameloblastomas, locally destructive odontogenic tumors of the jaw, by genomic analysis of archival material. Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible. We show that a frequently occurring SMO alteration encoding p.Leu412Phe is an activating mutation and that its effect on Hedgehog-pathway activity can be inhibited by arsenic trioxide (ATO), an anti-leukemia drug approved by the US Food and Drug Administration (FDA) that is currently in clinical trials for its Hedgehog-inhibitory activity. In a similar manner, ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib. Our findings establish a new paradigm for the diagnostic classification and treatment of ameloblastomas.

Original languageEnglish (US)
Pages (from-to)722-725
Number of pages4
JournalNature Genetics
Volume46
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Ameloblastoma
Mutation
Odontogenic Tumors
Maxilla
United States Food and Drug Administration
Mitogen-Activated Protein Kinases
Jaw
Mandible
Leukemia
Clinical Trials
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Genetics

Cite this

Sweeney, R. T., McClary, A. C., Myers, B. R., Biscocho, J., Neahring, L., Kwei, K. A., ... West, R. B. (2014). Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nature Genetics, 46(7), 722-725. https://doi.org/10.1038/ng.2986

Identification of recurrent SMO and BRAF mutations in ameloblastomas. / Sweeney, Robert T.; McClary, Andrew C.; Myers, Benjamin R.; Biscocho, Jewison; Neahring, Lila; Kwei, Kevin A.; Qu, Kunbin; Gong, Xue; Ng, Tony; Jones, Carol D.; Varma, Sushama; Odegaard, Justin I.; Sugiyama, Toshihiro; Koyota, Souichi; Rubin, Brian P.; Troxell, Megan; Pelham, Robert J.; Zehnder, James L.; Beachy, Philip A.; Pollack, Jonathan R.; West, Robert B.

In: Nature Genetics, Vol. 46, No. 7, 2014, p. 722-725.

Research output: Contribution to journalArticle

Sweeney, RT, McClary, AC, Myers, BR, Biscocho, J, Neahring, L, Kwei, KA, Qu, K, Gong, X, Ng, T, Jones, CD, Varma, S, Odegaard, JI, Sugiyama, T, Koyota, S, Rubin, BP, Troxell, M, Pelham, RJ, Zehnder, JL, Beachy, PA, Pollack, JR & West, RB 2014, 'Identification of recurrent SMO and BRAF mutations in ameloblastomas', Nature Genetics, vol. 46, no. 7, pp. 722-725. https://doi.org/10.1038/ng.2986
Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nature Genetics. 2014;46(7):722-725. https://doi.org/10.1038/ng.2986
Sweeney, Robert T. ; McClary, Andrew C. ; Myers, Benjamin R. ; Biscocho, Jewison ; Neahring, Lila ; Kwei, Kevin A. ; Qu, Kunbin ; Gong, Xue ; Ng, Tony ; Jones, Carol D. ; Varma, Sushama ; Odegaard, Justin I. ; Sugiyama, Toshihiro ; Koyota, Souichi ; Rubin, Brian P. ; Troxell, Megan ; Pelham, Robert J. ; Zehnder, James L. ; Beachy, Philip A. ; Pollack, Jonathan R. ; West, Robert B. / Identification of recurrent SMO and BRAF mutations in ameloblastomas. In: Nature Genetics. 2014 ; Vol. 46, No. 7. pp. 722-725.
@article{2ed6e09bb5ae4ebbae5ba45eae9c8d9a,
title = "Identification of recurrent SMO and BRAF mutations in ameloblastomas",
abstract = "Here we report the discovery of oncogenic mutations in the Hedgehog and mitogen-activated protein kinase (MAPK) pathways in over 80{\%} of ameloblastomas, locally destructive odontogenic tumors of the jaw, by genomic analysis of archival material. Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible. We show that a frequently occurring SMO alteration encoding p.Leu412Phe is an activating mutation and that its effect on Hedgehog-pathway activity can be inhibited by arsenic trioxide (ATO), an anti-leukemia drug approved by the US Food and Drug Administration (FDA) that is currently in clinical trials for its Hedgehog-inhibitory activity. In a similar manner, ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib. Our findings establish a new paradigm for the diagnostic classification and treatment of ameloblastomas.",
author = "Sweeney, {Robert T.} and McClary, {Andrew C.} and Myers, {Benjamin R.} and Jewison Biscocho and Lila Neahring and Kwei, {Kevin A.} and Kunbin Qu and Xue Gong and Tony Ng and Jones, {Carol D.} and Sushama Varma and Odegaard, {Justin I.} and Toshihiro Sugiyama and Souichi Koyota and Rubin, {Brian P.} and Megan Troxell and Pelham, {Robert J.} and Zehnder, {James L.} and Beachy, {Philip A.} and Pollack, {Jonathan R.} and West, {Robert B.}",
year = "2014",
doi = "10.1038/ng.2986",
language = "English (US)",
volume = "46",
pages = "722--725",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Identification of recurrent SMO and BRAF mutations in ameloblastomas

AU - Sweeney, Robert T.

AU - McClary, Andrew C.

AU - Myers, Benjamin R.

AU - Biscocho, Jewison

AU - Neahring, Lila

AU - Kwei, Kevin A.

AU - Qu, Kunbin

AU - Gong, Xue

AU - Ng, Tony

AU - Jones, Carol D.

AU - Varma, Sushama

AU - Odegaard, Justin I.

AU - Sugiyama, Toshihiro

AU - Koyota, Souichi

AU - Rubin, Brian P.

AU - Troxell, Megan

AU - Pelham, Robert J.

AU - Zehnder, James L.

AU - Beachy, Philip A.

AU - Pollack, Jonathan R.

AU - West, Robert B.

PY - 2014

Y1 - 2014

N2 - Here we report the discovery of oncogenic mutations in the Hedgehog and mitogen-activated protein kinase (MAPK) pathways in over 80% of ameloblastomas, locally destructive odontogenic tumors of the jaw, by genomic analysis of archival material. Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible. We show that a frequently occurring SMO alteration encoding p.Leu412Phe is an activating mutation and that its effect on Hedgehog-pathway activity can be inhibited by arsenic trioxide (ATO), an anti-leukemia drug approved by the US Food and Drug Administration (FDA) that is currently in clinical trials for its Hedgehog-inhibitory activity. In a similar manner, ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib. Our findings establish a new paradigm for the diagnostic classification and treatment of ameloblastomas.

AB - Here we report the discovery of oncogenic mutations in the Hedgehog and mitogen-activated protein kinase (MAPK) pathways in over 80% of ameloblastomas, locally destructive odontogenic tumors of the jaw, by genomic analysis of archival material. Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible. We show that a frequently occurring SMO alteration encoding p.Leu412Phe is an activating mutation and that its effect on Hedgehog-pathway activity can be inhibited by arsenic trioxide (ATO), an anti-leukemia drug approved by the US Food and Drug Administration (FDA) that is currently in clinical trials for its Hedgehog-inhibitory activity. In a similar manner, ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib. Our findings establish a new paradigm for the diagnostic classification and treatment of ameloblastomas.

UR - http://www.scopus.com/inward/record.url?scp=84903637379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903637379&partnerID=8YFLogxK

U2 - 10.1038/ng.2986

DO - 10.1038/ng.2986

M3 - Article

VL - 46

SP - 722

EP - 725

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 7

ER -